Oral medicine scientists from the Melbourne University have come up a vaccine that could negate or at least decrease the need for operations and antibiotic use in the treatment of severe gum disease. The project proponents from the institution’s Oral Health CRC have been working on the initiative for the past fifteen years. They intend to bring their methodology into the market by 2018, to most importantly cater for periodontitis patients across the globe. The periodontitis ailing often plagues the teeth’s supportive gum tissue and bone, resulting in tooth loss. In Australia alone, it’s affecting more than 50 percent of the population above age 65.
Published at the journal NPJ Vaccines, the undertaking also features analysis of the vaccine’s effectiveness by dentistry specialists from the Cambridge University. It specifically targets the enzymes produced by the bacterium Porphyromonas gingivalis, to in turn initiate an immune response. The occurrence further oversees the production of antibodies which nullify the pathogen’s destructive toxins. Eric Reynolds, CEO of Oral Health CRC, notes that the current surgery and antibiotic methodologies are helpful; though a bit ineffective since in most scenarios, the bacterium recapitulates, further causing the microbiological imbalance that facilitates continual of the disease.